For whom the endocannabinoid tolls: Modulation of innate immune function and implications for psychiatric disorders

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 64, Issue , 2016, Pages 167-180

  Henry, Rebecca J ^a   Kerr, Daniel M ^a   Finn, David P ^a   Roche, Michelle ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

2 AG; Anandamide; Depression; LPS; Poly I:C; Schizophrenia

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 [BIS(1,3 BENZODIOXOL 5 YL)HYDROXYMETHYL] 1 PIPERIDINECARBOXYLIC ACID 4 NITROPHENYL ESTER; ACYLGLYCEROL LIPASE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CELECOXIB; CYCLIC AMP; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DIACYLGLYCEROL; DIZOCILPINE; ENDOCANNABINOID; INTERLEUKIN 1BETA; LIPOPROTEIN LIPASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; N (3 FURYLMETHYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N ARACHIDONOYL DOPAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL; PHOSPHOLIPASE C; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 602; VANILLOID RECEPTOR 1; WWL 70; TOLL LIKE RECEPTOR;

BIOSYNTHESIS; CEREBELLUM; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE COURSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME SYNTHESIS; FIBROBLAST; HIPPOCAMPUS; HUMAN; HYDROLYSIS; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; LEUKOCYTE; MACROPHAGE; MAJOR DEPRESSION; MAST CELL; MONOCYTE; NATURAL KILLER CELL; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PREFRONTAL CORTEX; PRENATAL EXPOSURE; PREPULSE INHIBITION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYNAPTOSOME; ANIMAL; IMMUNOLOGY; MENTAL DISORDERS; METABOLISM; PHYSIOLOGY;

ANIMALS; ENDOCANNABINOIDS; HUMANS; IMMUNITY, INNATE; MENTAL DISORDERS; NEUROIMMUNOMODULATION; TOLL-LIKE RECEPTORS;

EID: 84941174945     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.03.006     Document Type: Review

References (231)

1. Akhondzadeh S., Tabatabaee M., Amini H., Ahmadi Abhari S.A., Abbasi S.H., Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007, 90:179-185.
2. Akira S. Innate immunity and adjuvants. Philos Trans R Soc Lond B Biol Sci 2011, 366:2748-2755.
3. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
4. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
5. Alhouayek M., Lambert D.M., Delzenne N.M., Cani P.D., Muccioli G.G. Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J 2011, 25:2711-2721.
6. Alhouayek M., Masquelier J., Cani P.D., Lambert D.M., Muccioli G.G. Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6. Proc Natl Acad Sci U S A 2013, 110:17558-17563.
7. Arroyo D.S., Soria J.A., Gaviglio E.A., Rodriguez-Galan M.C., Iribarren P. Toll-like receptors are key players in neurodegeneration. Int Immunopharmacol 2011, 11:1415-1421.
8. Asea A. Heat shock proteins and toll-like receptors. Handb Exp Pharmacol 2008, 111-127.
9. Baek J.H., Zheng Y., Darlington C.L., Smith P.F. Cannabinoid CB2 receptor expression in the rat brainstem cochlear and vestibular nuclei. Acta Otolaryngol 2008, 128:961-967.
10. Basset C., Holton J., O'Mahony R., Roitt I. Innate immunity and pathogen-host interaction. Vaccine 2003, 21(Suppl. 2):S12-S23.
11. Berdyshev E.V. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 2000, 108:169-190.
12. Bergink V., Gibney S.M., Drexhage H.A. Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol Psychiatry 2014, 75:324-331.
13. Berk M., Williams L.J., Jacka F.N., O'Neil A., Pasco J.A., Moylan S., et al. So depression is an inflammatory disease, but where does the inflammation come from?. BMC Med 2013, 11:200.
14. Bioque M., Garcia-Bueno B., Macdowell K.S., Meseguer A., Saiz P.A., Parellada M., et al. Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacology 2013, 38:2568-2577.
15. Bisogno T., Ligresti A., Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav 2005, 81:224-238.
16. Blankman J.L., Simon G.M., Cravatt B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007, 14:1347-1356.
17. Bowen J.L., Olson J.K. IFNgamma influences type I interferon response and susceptibility to Theiler's virus-induced demyelinating disease. Viral Immunol 2013, 26:223-238.
18. Brudek T., Winge K., Agander T.K., Pakkenberg B. Screening of Toll-like receptors expression in multiple system atrophy brains. Neurochem Res 2013, 38:1252-1259.
19. Bsibsi M., Ravid R., Gveric D., van Noort J.M. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002, 61:1013-1021.
20. Cabral G.A., Harmon K.N., Carlisle S.J. Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation. Adv Exp Med Biol 2001, 493:207-214.
21. Capuron L., Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004, 56:819-824.
22. Capuron L., Ravaud A., Miller A.H., Dantzer R. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 2004, 18:205-213.
23. Carlisle S.J., Marciano-Cabral F., Staab A., Ludwick C., Cabral G.A. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2002, 2:69-82.
24. Cavuoto P., McAinch A.J., Hatzinikolas G., Janovska A., Game P., Wittert G.A. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 2007, 364:105-110.
25. Chang Y.H., Lee S.T., Lin W.W. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J Cell Biochem 2001, 81:715-723.
26. Chang J.W., Niphakis M.J., Lum K.M., Cognetta A.B., Wang C., Matthews M.L., et al. Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates. Chem Biol 2012, 19:579-588.
27. Chiba T., Ueno S., Obara Y., Nakahata N. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells. J Pharm Pharmacol 2011, 63:636-647.
28. Chiurchiu V., Cencioni M.T., Bisicchia E., De Bardi M., Gasperini C., Borsellino G., et al. Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. Ann Neurol 2013, 73:626-636.
29. Chiurchiu V., Lanuti M., De Bardi M., Battistini L., Maccarrone M. The differential characterization of GPR55 receptor in human peripheral blood reveals a distinctive expression in monocytes and NK cells and a proinflammatory role in these innate cells. Int Immunol 2014, 27(3):153-160.
30. Cluny N.L., Keenan C.M., Duncan M., Fox A., Lutz B., Sharkey K.A. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice. J Pharmacol Exp Ther 2010, 334:973-980.
31. Cluny N.L., Vemuri V.K., Chambers A.P., Limebeer C.L., Bedard H., Wood J.T., et al. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 2010, 161:629-642.
32. Correa F., Mestre L., Docagne F., Guaza C. Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol 2005, 145:441-448.
33. Correa F., Docagne F., Clemente D., Mestre L., Becker C., Guaza C. Anandamide inhibits IL-12p40 production by acting on the promoter repressor element GA-12: possible involvement of the COX-2 metabolite prostamide E(2). Biochem J 2008, 409:761-770.
34. Correa F., Docagne F., Mestre L., Clemente D., Hernangomez M., Loria F., et al. A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochem Pharmacol 2009, 77:86-100.
35. Correa F., Hernangomez M., Mestre L., Loria F., Spagnolo A., Docagne F., et al. Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB. Glia 2010, 58:135-147.
36. Correa F., Hernangomez-Herrero M., Mestre L., Loria F., Docagne F., Guaza C. The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. Brain Behav Immun 2011, 25:736-749.
37. Costello D.A., Lynch M.A. Toll-like receptor 3 activation modulates hippocampal network excitability, via glial production of interferon-beta. Hippocampus 2013, 23:696-707.
38. Costola-de-Souza C., Ribeiro A., Ferraz-de-Paula V., Calefi A.S., Aloia T.P., Gimenes-Junior J.A., et al. Monoacylglycerol lipase (MAGL) inhibition attenuates acute lung injury in mice. PLoS One 2013, 8:e77706.
39. Cota D. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 2007, 23:507-517.
40. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384:83-87.
41. Cravatt B., Demarest K., Patricelli M., Bracey M., Giang D., Martin B., et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signalling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 2001, 98:9371-9376.
42. Cunningham C., Campion S., Teeling J., Felton L., Perry V.H. The sickness behaviour and CNS inflammatory mediator profile induced by systemic challenge of mice with synthetic double-stranded RNA (poly I:C). Brain Behav Immun 2007, 21:490-502.
43. Dantzer R. Cytokine-induced sickness behavior: where do we stand?. Brain Behav Immun 2001, 15:7-24.
44. Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol 2004, 500:399-411.
45. Dantzer R. Cytokine, sickness behavior, and depression. Neurol Clin 2006, 24:441-460.
46. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
47. Dantzer R., O'Connor J.C., Lawson M.A., Kelley K.W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011, 36:426-436.
48. De Laurentiis A., Fernandez-Solari J., Mohn C., Burdet B., Zorrilla Zubilete M.A., Rettori V. The hypothalamic endocannabinoid system participates in the secretion of oxytocin and tumor necrosis factor-alpha induced by lipopolysaccharide. J Neuroimmunol 2010, 221:32-41.
49. Dean B., Sundram S., Bradbury R., Scarr E., Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001, 103:9-15.
50. Deleidi M., Isacson O. Viral and inflammatory triggers of neurodegenerative diseases. Sci Transl Med 2012, 4:121ps123.
51. Deng C., Han M., Huang X.F. No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. Neurosci Bull 2007, 23:341-347.
52. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
53. Dhabhar F.S., Burke H.M., Epel E.S., Mellon S.H., Rosser R., Reus V.I., et al. Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. J Psychiatr Res 2009, 43:962-969.
54. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994, 372:686-691.
55. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 2002, 99:10819-10824.
56. Domschke K., Dannlowski U., Ohrmann P., Lawford B., Bauer J., Kugel H., et al. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 2008, 18:751-759.
57. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67:446-457.
58. Downer E.J., Clifford E., Gran B., Nel H.J., Fallon P.G., Moynagh P.N. Identification of the synthetic cannabinoid R(+)WIN55,212-2 as a novel regulator of IFN regulatory factor 3 activation and IFN-beta expression: relevance to therapeutic effects in models of multiple sclerosis. J Biol Chem 2011, 286:10316-10328.
59. Downer E.J., Clifford E., Amu S., Fallon P.G., Moynagh P.N. The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-beta expression via peroxisome proliferator-activated receptor-alpha. J Biol Chem 2012, 287:25440-25453.
60. Du H., Chen X., Zhang J., Chen C. Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-gamma. Br J Pharmacol 2011, 163:1533-1549.
61. Duncan M., Galic M.A., Wang A., Chambers A.P., McCafferty D.M., McKay D.M., et al. Cannabinoid 1 receptors are critical for the innate immune response to TLR4 stimulation. Am J Physiol Regul Integr Comp Physiol 2013, 305:R224-R231.
62. Echigo R., Sugimoto N., Yachie A., Ohno-Shosaku T. Cannabinoids inhibit peptidoglycan-induced phosphorylation of NF-kappaB and cell growth in U87MG human malignant glioma cells. Oncol Rep 2012, 28:1176-1180.
63. Eggan S.M., Hashimoto T., Lewis D.A. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 2008, 65:772-784.
64. Eggan S.M., Stoyak S.R., Verrico C.D., Lewis D.A. Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology 2010, 35:2060-2071.
65. Esposito G., Izzo A.A., Di Rosa M., Iuvone T. Selective cannabinoid CB1 receptor-mediated inhibition of inducible nitric oxide synthase protein expression in C6 rat glioma cells. J Neurochem 2001, 78:835-841.
66. Facchinetti F., Del Giudice E., Furegato S., Passarotto M., Leon A. Cannabinoids ablate release of TNF alpha in rat microglial cells stimulated with lipopolysaccharide. Glia 2003, 41:161-168.
67. Fernandez-Espejo E., Viveros M.P., Nunez L., Ellenbroek B.A., Rodriguez de Fonseca F. Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl) 2009, 206:531-549.
68. Field R., Campion S., Warren C., Murray C., Cunningham C. Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun 2010, 24:996-1007.
69. Galic M.A., Riazi K., Henderson A.K., Tsutsui S., Pittman Q.J. Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats. Neurobiol Dis 2009, 36:343-351.
70. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995, 232:54-61.
71. Gallily R., Breuer A., Mechoulam R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur J Pharmacol 2000, 406:R5-R7.
72. Gangloff M. Different dimerisation mode for TLR4 upon endosomal acidification?. Trends Biochem Sci 2012, 37:92-98.
73. Garcia-Gutierrez M.S., Perez-Ortiz J.M., Gutierrez-Adan A., Manzanares J. Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors. Br J Pharmacol 2010, 160:1773-1784.
74. Garate I., Garcia-Bueno B., Madrigal J.L., Caso J.R., Alou L., Gomez-Lus M.L., et al. Toll-like 4 receptor inhibitor TAK-242 decreases neuroinflammation in rat brain frontal cortex after stress. J Neuroinflammation 2014, 11:8.
75. Gazal M., Souza L.D., Fucolo B.A., Wiener C.D., Silva R.A., Pinheiro R.T., et al. The impact of cognitive behavioral therapy on IL-6 levels in unmedicated women experiencing the first episode of depression: a pilot study. Psychiatry Res 2013, 209:742-745.
76. Germain N., Boichot E., Advenier C., Berdyshev E.V., Lagente V. Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-alpha production by human mononuclear cells. Int Immunopharmacol 2002, 2:537-543.
77. Gibney S.M., McGuinness B., Prendergast C., Harkin A., Connor T.J. Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behav Immun 2013, 28:170-181.
78. Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004, 29:2108-2114.
79. Gong J.P., Onaivi E.S., Ishiguro H., Liu Q.R., Tagliaferro P.A., Brusco A., et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006, 1071:10-23.
80. Gui H., Sun Y., Luo Z.M., Su D.F., Dai S.M., Liu X. Cannabinoid receptor 2 protects against acute experimental sepsis in mice. Mediators Inflamm 2013, 2013. [741303].
81. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001, 98:3662-3665.
82. Henry R.J., Kerr D.M., Finn D.P., Roche M. FAAH-mediated modulation of TLR3-induced neuroinflammation in the rat hippocampus. J Neuroimmunol 2014, 276(1-2):126-134.
83. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991, 11:563-583.
84. Hernangomez M., Mestre L., Correa F.G., Loria F., Mecha M., Inigo P.M., et al. CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. Glia 2012, 60:1437-1450.
85. Hill M.N., Miller G.E., Ho W.S., Gorzalka B.B., Hillard C.J. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 2008, 41:48-53.
86. Hollis J.H., Jonaidi H., Lemus M., Oldfield B.J. The endocannabinoid arachidonylethanolamide attenuates aspects of lipopolysaccharide-induced changes in energy intake, energy expenditure and hypothalamic Fos expression. J Neuroimmunol 2011, 233:127-134.
87. Holmes C., Cunningham C., Zotova E., Woolford J., Dean C., Kerr S., et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009, 73:768-774.
88. Huang S.M., Bisogno T., Petros T.J., Chang S.Y., Zavitsanos P.A., Zipkin R.E., et al. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem 2001, 276:42639-42644.
89. Huang S.M., Bisogno T., Trevisani M., Al-Hayani A., De Petrocellis L., Fezza F., et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 2002, 99:8400-8405.
90. Hung Y.Y., Kang H.Y., Huang K.W., Huang T.L. Association between toll-like receptors expression and major depressive disorder. Psychiatry Res 2014, 220:283-286.
91. Hungund B.L., Vinod K.Y., Kassir S.A., Basavarajappa B.S., Yalamanchili R., Cooper T.B., et al. Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 2004, 9:184-190.
92. Ibi D., Nagai T., Nabeshima T., Yamada K. PolyI:C-induced neurodevelopmental animal model for schizophrenia. Nihon Shinkei Seishin Yakurigaku Zasshi 2011, 31:201-207.
93. Ignatowska-Jankowska B.M., Ghosh S., Crowe M.S., Kinsey S.G., Niphakis M.J., Abdullah R.A., et al. In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol 2014, 171:1392-1407.
94. Ishiguro H., Horiuchi Y., Ishikawa M., Koga M., Imai K., Suzuki Y., et al. Brain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry 2010, 67:974-982.
95. Javed A., Reder A.T. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Ther 2006, 110:35-56.
96. Jean-Gilles L., Gran B., Constantinescu C.S. Interaction between cytokines, cannabinoids and the nervous system. Immunobiology 2010, 215:606-610.
97. Jeon Y.J., Yang K.H., Pulaski J.T., Kaminski N.E. Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-kappa B/Rel activation. Mol Pharmacol 1996, 50:334-341.
98. Juhasz G., Chase D., Pegg E., Downey D., Toth Z.G., Stones K., et al. CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms. Neuropsychopharmacology 2009, 34:2019-2027.
99. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
100. Kent S., Rodriguez F., Kelley K.W., Dantzer R. Reduction in food and water intake induced by microinjection of interleukin-1 beta in the ventromedial hypothalamus of the rat. Physiol Behav 1994, 56:1031-1036.
101. Kerr D.M., Burke N.N., Ford G.K., Connor T.J., Harhen B., Egan L.J., et al. Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor. Neuroscience 2012, 204:53-63.
102. Kerr D.M., Harhen B., Okine B.N., Egan L.J., Finn D.P., Roche M. The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action. Br J Pharmacol 2013, 169:808-819.
103. Khella R., Short J.L., Malone D.T. CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice. Psychopharmacology (Berl) 2014, 231:3071-3087.
104. Kianian M., Al-Banna N.A., Kelly M.E., Lehmann C. Inhibition of endocannabinoid degradation in experimental endotoxemia reduces leukocyte adhesion and improves capillary perfusion in the gut. J Basic Clin Physiol Pharmacol 2013, 24:27-33.
105. Kiank C., Holtfreter B., Starke A., Mundt A., Wilke C., Schutt C. Stress susceptibility predicts the severity of immune depression and the failure to combat bacterial infections in chronically stressed mice. Brain Behav Immun 2006, 20:359-368.
106. Klegeris A., Bissonnette C.J., McGeer P.L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol 2003, 139:775-786.
107. Koethe D., Llenos I.C., Dulay J.R., Hoyer C., Torrey E.F., Leweke F.M., et al. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 2007, 114:1055-1063.
108. Koethe D., Giuffrida A., Schreiber D., Hellmich M., Schultze-Lutter F., Ruhrmann S., et al. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry 2009, 194:371-372.
109. Krishnan G., Chatterjee N. Endocannabinoids alleviate proinflammatory conditions by modulating innate immune response in muller glia during inflammation. Glia 2012, 60:1629-1645.
110. Kucerova J., Tabiova K., Drago F., Micale V. Therapeutic potential of cannabinoids in schizophrenia. Recent Pat CNS Drug Discov 2014, 9:13-25.
111. Leggett J.D., Aspley S., Beckett S.R., D'Antona A.M., Kendall D.A. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 2004, 141:253-262.
112. Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia 2010, 58:253-263.
113. Lin W., Bailey S.L., Ho H., Harding H.P., Ron D., Miller S.D., et al. The integrated stress response prevents demyelination by protecting oligodendrocytes against immune-mediated damage. J Clin Invest 2007, 117:448-456.
114. Liu J., Buisman-Pijlman F., Hutchinson M.R. Toll-like receptor 4: innate immune regulator of neuroimmune and neuroendocrine interactions in stress and major depressive disorder. Front Neurosci 2014, 8:309.
115. Long J.Z., Li W., Booker L., Burston J.J., Kinsey S.G., Schlosburg J.E., et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009, 5:37-44.
116. Long J.Z., Nomura D.K., Cravatt B.F. Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 2009, 16:744-753.
117. Lu Y., Peng F., Dong M., Yang H. Endocannabinoid 2-arachidonylglycerol protects primary cultured neurons against LPS-induced impairments in rat caudate nucleus. J Mol Neurosci 2014, 54:49-58.
118. Lucas K., Maes M. Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol Neurobiol 2013, 48:190-204.
119. Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 2008, 20(Suppl. 1):10-14.
120. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:664-675.
121. Maestroni G.J. The endogenous cannabinoid 2-arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein. FASEB J 2004, 18:1914-1916.
122. McKernan D.P., Dennison U., Gaszner G., Cryan J.F., Dinan T.G. Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype. Transl Psychiatry 2011, 1:e36.
123. McLaughlin R.J., Gobbi G. Cannabinoids and emotionality: a neuroanatomical perspective. Neuroscience 2012, 204:134-144.
124. McLinden K.A., Kranjac D., Deodati L.E., Kahn M., Chumley M.J., Boehm G.W. Age exacerbates sickness behavior following exposure to a viral mimetic. Physiol Behav 2012, 105:1219-1225.
125. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995, 50:83-90.
126. Merighi S., Gessi S., Varani K., Simioni C., Fazzi D., Mirandola P., et al. Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide. Br J Pharmacol 2012, 165:1773-1788.
127. Mestre L., Correa F., Arevalo-Martin A., Molina-Holgado E., Valenti M., Ortar G., et al. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem 2005, 92:1327-1339.
128. Mestre L., Correa F., Docagne F., Clemente D., Guaza C. The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. Biochem Pharmacol 2006, 72:869-880.
129. Mestre L., Docagne F., Correa F., Loria F., Hernangomez M., Borrell J., et al. A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol Cell Neurosci 2009, 40:258-266.
130. Mestre L., Inigo P.M., Mecha M., Correa F.G., Hernangomez-Herrero M., Loria F., et al. Anandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB(1) receptors. J Neuroinflammation 2011, 8:102.
131. Meyer U., Murray P.J., Urwyler A., Yee B.K., Schedlowski M., Feldon J. Adult behavioral and pharmacological dysfunctions following disruption of the fetal brain balance between pro-inflammatory and IL-10-mediated anti-inflammatory signaling. Mol Psychiatry 2008, 13:208-221.
132. Micale V., Di Marzo V., Sulcova A., Wotjak C.T., Drago F. Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol Ther 2013, 138:18-37.
133. Mogensen T.H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009, 22:240-273. [Table of Contents].
134. Molina-Holgado F., Lledo A., Guaza C. Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 1997, 8:1929-1933.
135. Molina-Holgado F., Molina-Holgado E., Guaza C. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett 1998, 433:139-142.
136. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 2009, 63:257-265.
137. Monteleone P., Bifulco M., Maina G., Tortorella A., Gazzerro P., Proto M.C., et al. Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol Res 2010, 61:400-404.
138. Muguruza C., Lehtonen M., Aaltonen N., Morentin B., Meana J.J., Callado L.F. Quantification of endocannabinoids in postmortem brain of schizophrenic subjects. Schizophr Res 2013, 148:145-150.
139. Muller N., Krause D., Dehning S., Musil R., Schennach-Wolff R., Obermeier M., et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010, 121:118-124.
140. Muller N., Wagner J.K., Krause D., Weidinger E., Wildenauer A., Obermeier M., et al. Impaired monocyte activation in schizophrenia. Psychiatry Res 2012, 198:341-346.
141. Muller-Vahl K.R., Emrich H.M. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev Neurother 2008, 8:1037-1048.
142. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
143. Murakami N., Sakata Y., Watanabe T. Central action sites of interleukin-1 beta for inducing fever in rabbits. J Physiol 1990, 428:299-312.
144. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001, 344:961-966.
145. Na K.S., Jung H.Y., Kim Y.K. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2012, 48:277-286.
146. Nagarkatti P., Pandey R., Rieder S.A., Hegde V.L., Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 2009, 1:1333-1349.
147. Navarrete C.M., Fiebich B.L., de Vinuesa A.G., Hess S., de Oliveira A.C., Candelario-Jalil E., et al. Opposite effects of anandamide and N-arachidonoyl dopamine in the regulation of prostaglandin E and 8-iso-PGF formation in primary glial cells. J Neurochem 2009, 109:452-464.
148. Naves R., Singh S.P., Cashman K.S., Rowse A.L., Axtell R.C., Steinman L., et al. The interdependent, overlapping, and differential roles of type I and II IFNs in the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 2013, 191:2967-2977.
149. Niphakis M.J., Cognetta A.B., Chang J.W., Buczynski M.W., Parsons L.H., Byrne F., et al. Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors. ACS Chem Neurosci 2013, 4:1322-1332.
150. Nomura D.K., Morrison B.E., Blankman J.L., Long J.Z., Kinsey S.G., Marcondes M.C., et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011, 334:809-813.
151. Nunez E., Benito C., Pazos M.R., Barbachano A., Fajardo O., Gonzalez S., et al. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 2004, 53:208-213.
152. O'Connor J.C., Lawson M.A., Andre C., Moreau M., Lestage J., Castanon N., et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 2009, 14:511-522.
153. Okun E., Griffioen K., Barak B., Roberts N.J., Castro K., Pita M.A., et al. Toll-like receptor 3 inhibits memory retention and constrains adult hippocampal neurogenesis. Proc Natl Acad Sci U S A 2010, 107:15625-15630.
154. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Perchuk A., Meozzi P.A., et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 2006, 1074:514-536.
155. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Meozzi P.A., Myers L., et al. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci 2008, 1139:434-449.
156. O'Neill L.A., Bryant C.E., Doyle S.L. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 2009, 61:177-197.
157. Ortega-Alvaro A., Aracil-Fernandez A., Garcia-Gutierrez M.S., Navarrete F., Manzanares J. Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice. Neuropsychopharmacology 2011, 36:1489-1504.
158. Ortega-Gutierrez S., Molina-Holgado E., Guaza C. Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia 2005, 52:163-168.
159. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Batkai S., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005, 115:1298-1305.
160. Overton H.A., Babbs A.J., Doel S.M., Fyfe M.C.T., Gardner L.S., Griffin G., et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 2006, 3:167-175.
161. Owens T. Toll-like receptors in neurodegeneration. Curr Top Microbiol Immunol 2009, 336:105-120.
162. Pacher P., Batkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006, 58:389-462.
163. Pandey G.N., Rizavi H.S., Ren X., Bhaumik R., Dwivedi Y. Toll-like receptors in the depressed and suicide brain. J Psychiatr Res 2014, 53:62-68.
164. Patterson P.H. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res 2009, 204:313-321.
165. Perry V.H. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 2004, 18:407-413.
166. Pertwee R.G. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci 2012, 367:3353-3363.
167. Pertwee R.G. Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proc Nutr Soc 2014, 73:96-105.
168. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002, 301:1020-1024.
169. Prescott S.M., Majerus P.W. Characterization of 1,2-diacylglycerol hydrolysis in human platelets. Demonstration of an arachidonoyl-monoacylglycerol intermediate. J Biol Chem 1983, 258:764-769.
170. Puffenbarger R.A., Boothe A.C., Cabral G.A. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 2000, 29:58-69.
171. Quan N., Banks W.A. Brain-immune communication pathways. Brain Behav Immun 2007, 21:727-735.
172. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27:24-31.
173. Realini N., Rubino T., Parolaro D. Neurobiological alterations at adult age triggered by adolescent exposure to cannabinoids. Pharmacol Res 2009, 60:132-138.
174. Ribeiro R., Wen J., Li S., Zhang Y. Involvement of ERK1/2, cPLA2 and NF-kappaB in microglia suppression by cannabinoid receptor agonists and antagonists. Prostaglandins Other Lipid Mediat 2013, 100-101:1-14.
175. Roche M., Kelly J.P., O'Driscoll M., Finn D.P. Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats. Immunology 2008, 125:263-271.
176. Rock R.B., Gekker G., Hu S., Sheng W.S., Cabral G.A., Martin B.R., et al. WIN55,212-2-mediated inhibition of HIV-1 expression in microglial cells: involvement of cannabinoid receptors. J Neuroimmune Pharmacol 2007, 2:178-183.
177. Rom S., Persidsky Y. Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J Neuroimmune Pharmacol 2013, 8:608-620.
178. Roser P., Haussleiter I.S. Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies. Curr Pharm Des 2012, 18:5141-5155.
179. Ryberg E., Larsson N., Sjogren S., Hjorth S., Hermansson N.O., Leonova J., et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007, 152:1092-1101.
180. Saito V.M., Wotjak C.T., Moreira F.A. Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?. Rev Bras Psiquiatr 2010, 32(Suppl. 1):S7-S14.
181. Saito A., Ballinger M.D., Pletnikov M.V., Wong D.F., Kamiya A. Endocannabinoid system: potential novel targets for treatment of schizophrenia. Neurobiol Dis 2013, 53:10-17.
182. Salaria S., Badkoobehi H., Rockenstein E., Crews L., Chana G., Masliah E., et al. Toll-like receptor pathway gene expression is associated with human immunodeficiency virus-associated neurodegeneration. J Neurovirol 2007, 13:496-503.
183. Salazar A., Gonzalez-Rivera B.L., Redus L., Parrott J.M., O'Connor J.C. Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge. Horm Behav 2012, 62:202-209.
184. Sardinha J., Kelly M.E., Zhou J., Lehmann C. Experimental cannabinoid 2 receptor-mediated immune modulation in sepsis. Mediators Inflamm 2014, 2014:978678.
185. Schaefer L. Complexity of danger: the diverse nature of damage-associated molecular patterns. J Biol Chem 2014, 289:35237-35245.
186. Segev A., Rubin A.S., Abush H., Richter-Levin G., Akirav I. Cannabinoid receptor activation prevents the effects of chronic mild stress on emotional learning and LTP in a rat model of depression. Neuropsychopharmacology 2014, 39:919-933.
187. Severa M., Rizzo F., Giacomini E., Salvetti M., Coccia E.M. IFN-beta and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networks. Cytokine Growth Factor Rev 2014, 10.1016/j.cytogfr.2014.11.005.
188. So E.Y., Kang M.H., Kim B.S. Induction of chemokine and cytokine genes in astrocytes following infection with Theiler's murine encephalomyelitis virus is mediated by the Toll-like receptor 3. Glia 2006, 53:858-867.
189. Song C., Wang H. Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:760-768.
190. Steiner A.A., Molchanova A.Y., Dogan M.D., Patel S., Petervari E., Balasko M., et al. The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors. J Physiol 2011, 589:2415-2431.
191. Stella N. Endocannabinoid signaling in microglial cells. Neuropharmacology 2009, 56:244-253.
192. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 2010, 58:1017-1030.
193. Storr M.A., Keenan C.M., Zhang H., Patel K.D., Makriyannis A., Sharkey K.A. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis 2009, 15:1678-1685.
194. Suarez-Pinilla P., Lopez-Gil J., Crespo-Facorro B. Immune system: a possible nexus between cannabinoids and psychosis. Brain Behav Immun 2014, 40:269-282.
195. Sugino H., Futamura T., Mitsumoto Y., Maeda K., Marunaka Y. Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:303-307.
196. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995, 215:89-97.
197. Sugiura T., Kondo S., Sukagawa A., Tonegawa T., Nakane S., Yamashita A., et al. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Eur J Biochem 1996, 240:53-62.
198. Sugiura T., Kondo S., Kishimoto S., Miyashita T., Nakane S., Kodaka T., et al. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 2000, 275:605-612.
199. Sun Y., Alexander S.P.H., Kendall D.A., Bennett A.J. Cannabinoids and PPAR alpha signalling. Biochem Soc Trans 2006, 34:1095-1097.
200. Szuster-Ciesielska A., Slotwinska M., Stachura A., Marmurowska-Michalowska H., Kandefer-Szerszen M. Neuroleptics modulate cytokine and reactive oxygen species production in blood leukocytes of healthy volunteers. Arch Immunol Ther Exp (Warsz) 2004, 52:59-67.
201. Takeda K., Akira S. Toll-like receptors. Curr Protoc Immunol 2007, 1-14. [Chapter 14: Unit 14 12].
202. Tan H., Ahmad T., Loureiro M., Zunder J., Laviolette S.R. The role of cannabinoid transmission in emotional memory formation: implications for addiction and schizophrenia. Front Psychiatry 2014, 5:73.
203. Teeling J.L., Perry V.H. Systemic infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms. Neuroscience 2009, 158:1062-1073.
204. Tham C.S., Whitaker J., Luo L., Webb M. Inhibition of microglial fatty acid amide hydrolase modulates LPS stimulated release of inflammatory mediators. FEBS Lett 2007, 581:2899-2904.
205. Trotta T., Porro C., Calvello R., Panaro M.A. Biological role of Toll-like receptor-4 in the brain. J Neuroimmunol 2014, 268:1-12.
206. Tschop J., Kasten K.R., Nogueiras R., Goetzman H.S., Cave C.M., England L.G., et al. The cannabinoid receptor 2 is critical for the host response to sepsis. J Immunol 2009, 183:499-505.
207. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998, 83:393-411.
208. Ueda N., Tsuboi K., Uyama T., Ohnishi T. Biosynthesis and degradation of the endocannabinoid 2-arachidonoylglycerol. Biofactors 2011, 37:1-7.
209. Uriguen L., Garcia-Fuster M.J., Callado L.F., Morentin B., La Harpe R., Casado V., et al. Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology (Berl) 2009, 206:313-324.
210. Urquhart P., Nicolaou A., Woodward D.F. Endocannabinoids and their oxygenation by cyclo-oxygenases, lipoxygenases and other oxygenases. Biochim Biophys Acta 2015, 1851(4):366-376.
211. van Noort J.M., Bsibsi M. Toll-like receptors in the CNS: implications for neurodegeneration and repair. Prog Brain Res 2009, 175:139-148.
212. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310:329-332.
213. Venkatasubramanian G., Debnath M. The TRIPS (Toll-like receptors in immuno-inflammatory pathogenesis) hypothesis: a novel postulate to understand schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 44:301-311.
214. Verhoeckx K.C., Korthout H.A., van Meeteren-Kreikamp A.P., Ehlert K.A., Wang M., van der Greef J., et al. Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. Int Immunopharmacol 2006, 6:656-665.
215. Walker J.M., Krey J.F., Chu C.J., Huang S.M. Endocannabinoids and related fatty acid derivatives in pain modulation. Chem Phys Lipids 2002, 121:159-172.
216. Wang D., Lin W., Pan Y., Kuang X., Qi X., Sun H. Chronic blockade of glucocorticoid receptors by RU486 enhances lipopolysaccharide-induced depressive-like behaviour and cytokine production in rats. Brain Behav Immun 2011, 25:706-714.
217. West A.P., Koblansky A.A., Ghosh S. Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol 2006, 22:409-437.
218. Wilhelmsen K., Khakpour S., Tran A., Sheehan K., Schumacher M., Xu F., et al. The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. J Biol Chem 2014, 289:13079-13100.
219. Yoshihara S., Morimoto H., Ohori M., Yamada Y., Abe T., Arisaka O. Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways. Int Arch Allergy Immunol 2005, 138:80-87.
220. Yu X.H., Cao C.Q., Martino G., Puma C., Morinville A., St-Onge S., et al. A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain. Pain 2010, 151:337-344.
221. Zajkowska Z.E., Englund A., Zunszain P.A. Towards a personalized treatment in depression: endocannabinoids, inflammation and stress response. Pharmacogenomics 2014, 15:687-698.
222. Zakharyan R., Boyajyan A. Inflammatory cytokine network in schizophrenia. World J Biol Psychiatry 2014, 15:174-187.
223. Zavitsanou K., Garrick T., Huang X.F. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:355-360.
224. Zhang J., Chen C. Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J Biol Chem 2008, 283:22601-22611.
225. Zhang H.Y., Gao M., Liu Q.R., Bi G.H., Li X., Yang H.J., et al. Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci U S A 2014, 111:E5007-E5015.
226. Zhao Y., Liu Y., Zhang W., Xue J., Wu Y.Z., Xu W., et al. WIN55212-2 ameliorates atherosclerosis associated with suppression of pro-inflammatory responses in ApoE-knockout mice. Eur J Pharmacol 2010, 649:285-292.
227. Zhong P., Wang W., Pan B., Liu X., Zhang Z., Long J.Z., et al. Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling. Neuropsychopharmacology 2014, 39:1763-1776.
228. Zoppi S., Perez Nievas B.G., Madrigal J.L., Manzanares J., Leza J.C., Garcia-Bueno B. Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinflammation. Neuropsychopharmacology 2011, 36:805-818.
229. Zoppi S., Madrigal J.L., Caso J.R., Garcia-Gutierrez M.S., Manzanares J., Leza J.C., et al. Regulatory role of the cannabinoid CB2 receptor in stress-induced neuroinflammation in mice. Br J Pharmacol 2014, 171:2814-2826.
230. Zuardi A.W., Crippa J.A., Hallak J.E., Bhattacharyya S., Atakan Z., Martin-Santos R., et al. A critical review of the antipsychotic effects of cannabidiol: 30years of a translational investigation. Curr Pharm Des 2012, 18:5131-5140.
231. Zunszain P.A., Hepgul N., Pariante C.M. Inflammation and depression. Curr Top Behav Neurosci 2013, 14:135-151.